<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Bone Sarcoma Treatment &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/bone-sarcoma-treatment/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 20 Jan 2026 19:48:45 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Bone Sarcoma Treatment &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>132 UPSB Patients Treated: Insights from COSS Study</title>
		<link>https://bioengineer.org/132-upsb-patients-treated-insights-from-coss-study/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 19:48:19 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Bone cancer misclassification challenges]]></category>
		<category><![CDATA[Bone Sarcoma Treatment]]></category>
		<category><![CDATA[Cooperative Osteosarcoma Study Group]]></category>
		<category><![CDATA[COSS Study]]></category>
		<category><![CDATA[İşte içerik için uygun 5 etiket: **UPSB]]></category>
		<category><![CDATA[Multimodal Therapy]]></category>
		<category><![CDATA[Multimodal treatment strategies]]></category>
		<category><![CDATA[Patient Outcomes Analysis** **Kısa açıklama:** 1. **UPSB:** Makalenin ana konusu olan hastalığın kısaltması (Kemikte Farklılaşmamış Pleomorfik Sarkom). 2. **COSS Study:**]]></category>
		<category><![CDATA[Psychosocial support in oncology]]></category>
		<category><![CDATA[Undifferentiated Pleomorphic Sarcoma of Bone]]></category>
		<guid isPermaLink="false">https://bioengineer.org/132-upsb-patients-treated-insights-from-coss-study/</guid>

					<description><![CDATA[In a significant advancement within the realm of orthopedic oncology, the latest study conducted by Bielack et al. sheds light on Undifferentiated Pleomorphic Sarcoma of Bone (UPSB). This sarcoma, previously characterized by its challenging prognosis and limited treatment options, has now been the subject of intense scrutiny by the Cooperative Osteosarcoma Study Group (COSS), which [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319131</post-id>	</item>
	</channel>
</rss>
